SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $11.00.

SABS has been the subject of several recent analyst reports. HC Wainwright increased their price target on SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Citigroup initiated coverage on shares of SAB Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $11.00 price target on the stock. Chardan Capital lifted their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price target on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $22,954,000. Perceptive Advisors LLC raised its holdings in shares of SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after purchasing an additional 5,628,533 shares during the last quarter. Commodore Capital LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $8,847,000. RA Capital Management L.P. acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $8,847,000. Finally, Woodline Partners LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $5,730,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.44 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The stock has a market cap of $263.02 million, a PE ratio of -1.63 and a beta of 0.54. The stock has a 50-day moving average of $3.78 and a 200-day moving average of $3.87. SAB Biotherapeutics has a one year low of $1.60 and a one year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). As a group, sell-side analysts expect that SAB Biotherapeutics will post -1.19 earnings per share for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.